Taking double Covid-19 hits, Merck writes off $170M for scrapped drug, highlights $600M in missed sales
Merck acquired MK-7110, the Covid-19 drug originally developed by OncoImmune, for $425 million in cash. The decision to scrap it has cost at least …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
